Introduction

The rare inherited bleeding illness known as Glanzmann thrombasthenia (GT) is typified by a qualitative or quantitative reduction in the glycoprotein (GP) IIb/IIIa complex on the surface of platelets. This deficit causes a bleeding tendency by preventing platelets from aggregating. Males and females are equally affected by the autosomal recessive disorder, which was initially described by Dr. Eduard Glanzmann in 1918. A variety of bleeding symptoms, from minor to potentially fatal, are linked to GT.¹

Pathophysiology & Clinical Features of Glanzmann Thrombasthenia

The creation of a hemostatic plug during the clotting process depends on platelet aggregation, which is facilitated by the GP IIb/IIIa complex, a fibrinogen receptor. Because the GP IIb/IIIa complex is either lacking or defective in GT patients, fibrinogen is unable to bind to platelets, inhibiting the cross-linking of platelets required for the development of clots. Prolonged bleeding and aberrant platelet aggregation are the outcomes of this dysfunction.¹

The way that GT manifests clinically can differ greatly across those who are affected; some may have very minimal signs, while others have severe and frequent bleeding episodes. In GT, bleeding tendencies are typically noticeable from an early age and can be brought on by small traumas or even happen on their own.

The way that GT manifests clinically can differ greatly across those who are affected; some may have very minimal signs, while others have severe and frequent bleeding episodes. In GT, bleeding tendencies are typically noticeable from an early age and can be brought on by small traumas or even happen on their own.

• Mucocutaneous Bleeding: 
  • Epistaxis: One of the most typical signs of GT is frequent, severe nosebleeds. These outbursts can be difficult to control and can necessitate visiting the doctor
  • Gingival Bleeding: Another common symptom is bleeding from the gums, even after minimal trauma like brushing your teeth
  • Purpura and Ecchymosis: With little to no visible trauma, patients with GT frequently have purpura, or tiny bruises, and ecchymosis, or larger bruises. There's a chance these bruises are extensive, which can be extremely uncomfortable and unsettling³
  • Menorrhagia: Heavy menstrual bleeding (menorrhagia) is a typical occurrence in women with GT. This condition can cause severe anemia and necessitate medical attention or perhaps surgery
• Bleeding from Minor Injuries
  • Prolonged Bleeding: People with GT may experience prolonged bleeding from even small wounds or abrasions. Without using medical procedures like suturing or the application of hemostatic medications, this bleeding may be difficult to control
  • Post-Surgical Bleeding: After surgical treatments such as tooth extractions, individuals with GT are highly susceptible to severe bleeding. Consequently, any surgical intervention involving these individuals must be carefully planned for and must incorporate preventive measures
• Blodging in the intestines: Gastrointestinal bleeding is a rare but possible side effect in people with GT. Hematemesis (blood in the vomit), melena (black, tarry stools), or rectal bleeding are possible manifestations of this. If not treated right away, gastrointestinal bleeding in GT patients can become serious and potentially fatal⁴
• Hemorrhage within the Brain: Intracerebral hemorrhage is one of the most serious side effects of GT and, while uncommon, can be lethal. This risk emphasizes how crucial it is to diagnose the illness as soon as possible and treat it carefully, especially in newborns and early children. 
• Bleeding during Pregnancy and Childbirth: Because of the higher risk of bleeding, women with GT confront many difficulties throughout pregnancy and childbirth. These can include bleeding issues following a caesarean section, as well as antepartum and postpartum hemorrhages. Effective risk management requires diverse teamwork and close observation.

Diagnosis of Glanzmann Thrombasthenia

Platelet function tests, genetic testing, and clinical history are usually used to make the diagnosis of GT. Studies on platelet aggregation show that, in response to all physiologic agonists but ristocetin, which is indicative of GT, there is no aggregation. Confirmation of the GP IIb/IIIa complex's absence or functioning can be achieved using flow cytometry. Mutations in the ITGA2B or ITGB3 genes, which encode the GP IIb and GP IIIa subunits, respectively, can be detected by genetic testing.⁵

Management of Glanzmann Thrombasthenia

Since GT has no known cure, the main goals of care are to stop and treat bleeding episodes. Local treatments include applying pressure and topical hemostatic medications, which might be adequate for small amounts of bleeding. Antifibrinolytic drugs, platelet transfusions, or recombinant activated factor VII (rFVIIa) may be necessary in cases of more severe bleeding. Hormonal therapy may be helpful for women who experience menorrhagia. In addition to being crucial for controlling GT, preventive strategies include avoiding high-risk activities and carefully arranging surgical procedures.²

Conclusion

An uncommon but dangerous bleeding illness, Glanzmann thrombasthenia can cause anything from minor mucocutaneous bleeding to potentially fatal hemorrhages. To reduce the likelihood of serious bleeding issues and enhance the quality of life for those who are affected, early identification and cautious management are crucial. The management of this difficult ailment may improve in the future because of developments in targeted medications and genetic testing.